AX-2025-021213

Gonadorelin · 2 mg declared · Bachem Holding (Suzhou) Co., Ltd. · lot BCH-2510-F6239

FAILIDENTITY CONSISTENT

Report ID: AX-2025-021213
Compound: Gonadorelin
Compound class: Hypothalamic and posterior-pituitary hormones
Supplier: BCH — Bachem Holding (Suzhou) Co., Ltd.
Batch / lot: BCH-2510-F6239
Declared label claim: 2mg
Laboratory: Janoshik Analytical
Assay date: 11 Oct 2025
Submitted: 31 Oct 2025
Quarter: 2025-Q4
Submitter: p.brandt
Sample provenance: Laboratory-retained

Section 1

Results

Measured against the index acceptance specification for the hypothalamic and posterior-pituitary hormones class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.16	% area	≥ 98.5	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.84	% area	≤ 1.5	FAIL
Largest single impurity	RP-HPLC — ring-opened pGlu (+18 Da)	1.12	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	1181.5825	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1181.5800	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-2.1	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.56	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	3.04	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.54	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.13	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.65	min	8.68 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	64,300	—	≥ 20,000	PASS
Resolution to nearest impurity	vs C-terminal free acid (+1 Da)	1.14	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 64,300, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.12 % impurity against a 98.16 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Gonadorelin — main peak	8.65	4,770,880	98.16	—
2	ring-opened pGlu (+18 Da)	8.19	54,435	1.12	+18.011
3	des-Gly10-NH2 (−74 Da)	8.37	21,871	0.45	-74.048
4	oxidised Trp (+16 Da)	8.33	8,263	0.17	+15.995
5	C-terminal free acid (+1 Da)	8.81	4,860	0.10	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1181.5825 Da, computed from C55H75N17O13. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1181.5800 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	394.8681	394.8673	-0.0008	7.7
2+	591.7985	591.7973	-0.0012	49.8
1+	1182.5898	1182.5873	-0.0025	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.94	98.16	divergence +0.32 pp vs batch median
Total impurities (% area)	1.06	1.84
Largest single impurity (% area)	not stated	1.12
Water (%)	3.5	5.56
Counter-ion (%)	not stated	3.04
Peptide content (%w/w)	91.7	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Laboratory-retained
Evidentiary weight: Provenance documented, selection uncontrolled.
Chain of custody: Laboratory retained sample (−20 °C, 15 d since original receipt) → re-assay.
Assay date: 11 Oct 2025
Submitted to the index: 31 Oct 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot BCH-2510-F6239 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-021207	BCH-2510-F6239	Janoshik	2025-Q4	98.62	5.19	—	Supplier-supplied	0	PASS
AX-2025-021208	BCH-2510-F6239	Janoshik	2025-Q4	98.60	5.27	95.3	Supplier-supplied	1	MARGINAL
AX-2025-021209	BCH-2510-F6239	Janoshik	2025-Q4	99.33	5.16	97.7	Supplier-supplied	0	PASS
AX-2025-021210	BCH-2510-F6239	Janoshik	2025-Q4	99.02	5.73	104.5	Supplier-supplied	1	MARGINAL
AX-2025-021211	BCH-2510-F6239	Janoshik	2025-Q4	98.91	5.56	—	Supplier-supplied	1	MARGINAL
AX-2025-021212	BCH-2510-F6239	PeptideMeter	2025-Q4	98.94	5.22	—	Supplier-supplied	1	MARGINAL
AX-2026-043506	BCH-2510-F6239	Janoshik	2025-Q4	98.08	5.44	—	Buyer-sourced	0	FAIL
AX-2025-021214	BCH-2510-F6239	VendorInvestigate	2025-Q4	98.62	5.59	—	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Gonadorelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042914	MKM	MKM-2604-A2596	Janoshik	2026-Q2	99.93	5.19	—	Supplier-supplied	0	PASS
AX-2026-042911	MKM	MKM-2604-A2596	Medutest	2026-Q2	99.08	5.55	—	Buyer-sourced	1	MARGINAL
AX-2026-042916	MKM	MKM-2604-A2596	VendorInvestigate	2026-Q2	99.36	4.91	102.1	Buyer-sourced	1	MARGINAL
AX-2026-042038	TFC	TFC-2511-E6450	Janoshik	2026-Q2	99.03	2.63	101.8	Supplier-supplied	0	PASS
AX-2026-042039	TFC	TFC-2511-E6450	Janoshik	2026-Q2	99.39	2.81	96.2	Supplier-supplied	0	PASS
AX-2026-042917	MKM	MKM-2604-A2596	Kestrel	2026-Q2	99.76	5.43	105.7	Buyer-sourced	1	MARGINAL
AX-2026-042944	MKM	MKM-2512-N3913	PeptideMeter	2026-Q2	99.92	5.75	91.1	Supplier-supplied	0	PASS
AX-2026-042033	TFC	TFC-2511-E6450	PeptideMeter	2026-Q2	99.48	2.96	—	Supplier-supplied	1	MARGINAL

Other recent BCH records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043574	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.75	8.85	97.9	Supplier-supplied	1	FAIL
AX-2026-043503	BPC-157	BCH-2603-G6422	Janoshik	2026-Q3	98.46	4.32	—	Supplier-supplied	1	MARGINAL
AX-2026-043575	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.44	9.19	104.8	Supplier-supplied	1	FAIL
AX-2026-043539	CJC-1295 with DAC	BCH-2607-H7307	Janoshik	2026-Q3	98.12	5.78	100.6	Supplier-supplied	1	MARGINAL
AX-2026-043504	BPC-157	BCH-2603-G6422	Janoshik	2026-Q3	98.38	4.45	95.5	Supplier-supplied	1	MARGINAL
AX-2026-043502	BPC-157	BCH-2603-G6422	PeptideMeter	2026-Q3	97.72	4.86	—	Buyer-sourced	1	FAIL
AX-2026-043501	BPC-157	BCH-2603-G6422	PeptideMeter	2026-Q3	98.37	4.75	100.8	Supplier-supplied	1	MARGINAL
AX-2026-043573	N-Acetyl Semax Amide	BCH-2602-E8253	Janoshik	2026-Q3	97.47	8.59	—	Supplier-supplied	1	FAIL